Replies to post #121018 on Biotech Values

[DewDiligence]

The Vemurafenib + Vervoy melanoma program (#msg-63823816) is clearly one to watch.

We may soon need a scorecard to keep track of the various programs testing two (or more) targeted cancer drugs.